Novartis AG (SWX:NOVN)
133.08
-1.04 (-0.78%)
Nov 6, 2026, 5:30 PM CET
Novartis AG Revenue
Novartis AG had revenue of $15.03B USD in the quarter ending September 30, 2026, with 4.67% growth. This brings the company's total for the last twelve months to $57.36B, up 1.76% year-over-year. In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth. That makes Novartis AG the 219th largest company in the world by revenue and 5th in Switzerland.
Revenue (ttm)
$57.36B
Revenue Growth
+1.76%
P/S Ratio
5.25
Revenue / Employee
$762.14K
Employees
75,267
Market Cap
251.34B CHF
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Novartis AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | -5.17B | -9.97% |
| Dec 31, 2022 | 51.83B | -1.05B | -1.98% |
| Dec 31, 2021 | 52.88B | 2.98B | 5.97% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | -4.04B | -8.05% |
| Dec 31, 2017 | 50.14B | 699.00M | 1.41% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Sandoz Group AG | 9.43B |
| Alcon | 8.78B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.79B |
| Galenica AG | 4.29B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.64B |
Novartis AG News
- 6 hours ago - Novartis price target raised to CHF 150 from CHF 135 at Citi - TheFly
- 3 days ago - Novartis: 3 Key Takeaways for Long-Term Investors - The Motley Fool
- 3 days ago - BioArtic's BrainTransporter Collaboration With Novartis Ends Following Program Discontinuation - Nasdaq
- 4 days ago - BioArctic collaborator Novartis terminates agreement - PRNewsWire
- 4 days ago - 6 dividend stocks for investors who want to cut their exposure to the S&P 500 - Market Watch
- 4 days ago - Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target - Reuters
- 5 days ago - Companies promised AI gains— here's how the payoff showed up in earnings - CNBC
- 7 days ago - Novartis downgraded to Sell at Deutsche Bank on pending exclusivity cliff - TheFly